JP5547487B2 - 抗癌化合物の投与方法 - Google Patents
抗癌化合物の投与方法 Download PDFInfo
- Publication number
- JP5547487B2 JP5547487B2 JP2009535056A JP2009535056A JP5547487B2 JP 5547487 B2 JP5547487 B2 JP 5547487B2 JP 2009535056 A JP2009535056 A JP 2009535056A JP 2009535056 A JP2009535056 A JP 2009535056A JP 5547487 B2 JP5547487 B2 JP 5547487B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- day
- week
- amount
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Description
以下を含有するバイアル
化合物1 0.150g、
塩酸または水酸化ナトリウムによってpH5に調整した5%デキストロース溶液15ml。
食塩水500mlを含有する輸液バッグに患者に投与される用量を入れ、次に薬物添加後の最終体積が常に500mlであるように等体積をバックから除去した。得られた溶液を3から24時間に及ぶ時間で静脈内投与した。注入前後に、静脈を食塩水10mlで5分間にわたって洗浄した。
Claims (1)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06123440.7 | 2006-11-03 | ||
EP06123440 | 2006-11-03 | ||
PCT/EP2007/061491 WO2008052931A1 (en) | 2006-11-03 | 2007-10-25 | A method of administering an antitumor compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010523470A JP2010523470A (ja) | 2010-07-15 |
JP5547487B2 true JP5547487B2 (ja) | 2014-07-16 |
Family
ID=38702074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009535056A Expired - Fee Related JP5547487B2 (ja) | 2006-11-03 | 2007-10-25 | 抗癌化合物の投与方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100256160A1 (ja) |
EP (1) | EP2117539B1 (ja) |
JP (1) | JP5547487B2 (ja) |
CN (1) | CN101588800B (ja) |
AR (1) | AR063459A1 (ja) |
AT (1) | ATE479432T1 (ja) |
AU (1) | AU2007316217A1 (ja) |
BR (1) | BRPI0717998A2 (ja) |
CA (1) | CA2668363A1 (ja) |
CL (1) | CL2007003172A1 (ja) |
DE (1) | DE602007008949D1 (ja) |
EA (1) | EA200970444A1 (ja) |
ES (1) | ES2350803T3 (ja) |
MX (1) | MX2009004607A (ja) |
TW (1) | TW200827361A (ja) |
WO (1) | WO2008052931A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2415907T3 (es) | 2008-07-24 | 2013-07-29 | Nerviano Medical Sciences S.R.L. | Combinación terapéutica que comprende un inhibidor de cinasas aurora y agentes antiproliferativos |
US20110117212A1 (en) * | 2008-07-24 | 2011-05-19 | Nerviano Medical Sciences S.R.L. | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent |
CN105037399B (zh) * | 2014-04-17 | 2017-04-26 | 深圳永泽医药股份有限公司 | 一类Bcr‑Abl双倍体抑制剂及制备方法与用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ518847A (en) * | 1999-11-15 | 2004-02-27 | Pharma Mar S | Aplidine treatment of cancers |
WO2003024926A2 (en) * | 2001-09-21 | 2003-03-27 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7141568B2 (en) * | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
CN1917885A (zh) * | 2004-02-06 | 2007-02-21 | 施瑞修德制药公司 | 抗癌疗法 |
TW200808311A (en) * | 2006-03-30 | 2008-02-16 | Nerviano Medical Sciences Srl | Use of a kinase inhibitor for the treatment of particular resistant tumors |
-
2007
- 2007-10-25 WO PCT/EP2007/061491 patent/WO2008052931A1/en active Application Filing
- 2007-10-25 US US12/513,290 patent/US20100256160A1/en not_active Abandoned
- 2007-10-25 AU AU2007316217A patent/AU2007316217A1/en not_active Abandoned
- 2007-10-25 BR BRPI0717998-7A patent/BRPI0717998A2/pt not_active IP Right Cessation
- 2007-10-25 AT AT07821854T patent/ATE479432T1/de active
- 2007-10-25 CN CN2007800405595A patent/CN101588800B/zh not_active Expired - Fee Related
- 2007-10-25 MX MX2009004607A patent/MX2009004607A/es active IP Right Grant
- 2007-10-25 ES ES07821854T patent/ES2350803T3/es active Active
- 2007-10-25 JP JP2009535056A patent/JP5547487B2/ja not_active Expired - Fee Related
- 2007-10-25 CA CA002668363A patent/CA2668363A1/en not_active Abandoned
- 2007-10-25 EP EP07821854A patent/EP2117539B1/en active Active
- 2007-10-25 EA EA200970444A patent/EA200970444A1/ru unknown
- 2007-10-25 DE DE602007008949T patent/DE602007008949D1/de active Active
- 2007-10-31 TW TW096140931A patent/TW200827361A/zh unknown
- 2007-11-02 CL CL200703172A patent/CL2007003172A1/es unknown
- 2007-11-02 AR ARP070104888A patent/AR063459A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0717998A2 (pt) | 2013-12-03 |
DE602007008949D1 (de) | 2010-10-14 |
MX2009004607A (es) | 2009-05-22 |
TW200827361A (en) | 2008-07-01 |
EP2117539B1 (en) | 2010-09-01 |
ES2350803T3 (es) | 2011-01-27 |
EP2117539A1 (en) | 2009-11-18 |
CN101588800B (zh) | 2012-01-04 |
ATE479432T1 (de) | 2010-09-15 |
AU2007316217A1 (en) | 2008-05-08 |
US20100256160A1 (en) | 2010-10-07 |
CL2007003172A1 (es) | 2008-06-27 |
CA2668363A1 (en) | 2008-05-08 |
AR063459A1 (es) | 2009-01-28 |
EA200970444A1 (ru) | 2009-12-30 |
CN101588800A (zh) | 2009-11-25 |
WO2008052931A1 (en) | 2008-05-08 |
JP2010523470A (ja) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3173100B1 (en) | Therapeutic combination comprising a cdks inhibitor and oxaliplatin | |
KR101673731B1 (ko) | 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법 | |
JP5417385B2 (ja) | 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用 | |
KR20130073948A (ko) | 암 치료를 위한 새로운 병용 요법 | |
TW201625243A (zh) | 用於治療黑素瘤之藥物組合 | |
EP1201247B1 (en) | Treatment of metastatic renal cell carcinoma | |
JP5547487B2 (ja) | 抗癌化合物の投与方法 | |
RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
EP2902028A1 (en) | Drug composition for treating tumors and application thereof | |
EP2313097B1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
KR102637904B1 (ko) | 3-케토아실 CoA 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
EP2344156B1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent | |
TWI813694B (zh) | 抗腫瘤劑及腫瘤治療方法 | |
WO2022167999A1 (en) | Combination therapy for cancer treatment | |
CN116672345A (zh) | Parp抑制剂和细胞毒性剂的联合产品及其用途 | |
US20100022553A1 (en) | Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib | |
CA2638270A1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and imatinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101020 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130208 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130208 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130313 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131107 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140314 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140422 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140515 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5547487 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |